research Topical immunomodulators in dermatology.
Topical immunomodulators are effective and safe for treating immune-related skin conditions.
Search
for
Sort by
Research
330-360 / 1000+ results
research Efficacy and safety of mycophenolate mofetil for lichen planopilaris
Mycophenolate mofetil was effective for most patients in treating scarring hair loss, but some had side effects.
research A(1-7) reduces pathologies associated with SLE in MRL-lpr mice
A(1-7) treatment reduces symptoms of lupus in mice.
research ODP342 Panhypopituitarism Induced by CTLA-4 and PD-1/PD-L1 Inhibitor Immunotherapy
Immunotherapy for cancer caused a patient to develop a condition affecting hormone production, requiring ongoing hormone replacement therapy.
research The Effect of JAK Inhibitor on the Survival, Anagen Re-Entry, and Hair Follicle Immune Privilege Restoration in Human Dermal Papilla Cells
Ruxolitinib may help treat hair loss by reducing inflammation, promoting hair growth signals, and protecting hair follicle immunity.
research Pathogenesis and management of TRPV3-related Olmsted syndrome
EGFR and mTOR inhibitors may help manage Olmsted syndrome symptoms.
research Mesenchymal Stem Cells from Mouse Hair Follicles Inhibit the Development of Type 1 Diabetes
Mouse hair follicle stem cells can help prevent Type 1 Diabetes.
research Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)
Deuruxolitinib effectively promotes hair regrowth in adults with alopecia areata.
research Three cases of immune‐mediated adnexal skin disease treated with cyclosporin
Cyclosporin effectively and safely treated skin diseases in three pets with no side effects.
research Prescribers alerted to potential adverse effects of finasteride and montelukast
research COMPARATIVE EFFICACY OF TOPICAL CLOBETASOL PROPIONATE 0.05% OINTMENT AND TOPICAL TACROLIMUS 0.1% OINTMENT IN THE TREATMENT OF ALOPECIA AREATA
Clobetasol propionate 0.05% ointment is more effective than tacrolimus 0.1% ointment for treating alopecia areata.
research ANTI-CD19 MONOCLONAL ANTIBODY FOR SYSTEMIC LUPUS ERYTHEMATOSUS AND NEUROMYELITIS OPTICA SPECTRUM DISORDER
Anti-CD19 therapy may help treat SLE and NMOSD.
research 307 Dermatologic toxicities associated with chronic gamma-secretase inhibitor treatment for desmoid tumor
Most patients experienced mild to moderate skin problems during a trial for a desmoid tumor treatment.
research 0054 Treg-targeted therapies restrain disease in a murine model of alopecia areata
Enhancing Tregs can protect against alopecia areata.
research Drug pipeline 2Q22 — a downturn in approvals
Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.
research Sequential Immunotherapy with Tofacitinib and Low-Dose IL-2 Induces Sustained Remission in Alopecia Areata: A Proof-of-concept monocentric study
Tofacitinib and low-dose IL-2 may help maintain hair regrowth in alopecia areata without ongoing treatment.
research Refractory cutaneous lichenoid sarcoidosis treated with tranilast
Tranilast successfully treated a man's skin sarcoidosis when other treatments failed.
research Finasteride blocks progesterone synthesis in MA-10 Leydig tumor cells
research P075 A randomized controlled trial comparing the efficacy and safety of oral tofacitinib vs. methotrexate in moderate-to-severe alopecia areata
Tofacitinib was more effective than methotrexate for treating alopecia areata.
research Adverse events of the thyroid peroxidase inhibitor methimazole in the treatment of hyperthyroidism: a comprehensive analysis from the first quarter of 2004 to the first quarter of 2025
Methimazole for hyperthyroidism has known and new side effects needing more study for safety.
research Three Cases of Alopecia Following Clinical Islet Transplantation
Some patients developed hair loss after islet cell transplant possibly due to their immune-suppressing medications.
research Hair today, gone tomorrow
Two drugs, tofacitinib and ruxolitinib, may help regrow hair by activating hair follicles.
research A Case of Topical Ruxolitinib Treatment Failure in Alopecia Areata
Topical ruxolitinib failed to regrow hair in a 66-year-old with alopecia areata.
research A Low Dose of Rapamycin Promotes Hair Cell Differentiation by Enriching SOX2+ Progenitors in the Neonatal Mouse Inner Ear Organoids.
A low dose of rapamycin increases inner ear hair cell creation by boosting SOX2+ cell numbers.
research Diphencyprone and topical tacrolimus as two topical immunotherapeutic modalities. Are they effective in the treatment of alopecia areata among Egyptian patients? A study using CD4, CD8 and MHC II as markers
Diphencyprone is effective for treating patchy hair loss in alopecia areata, but tacrolimus is not.
research Low disease activity—irrespective of serologic status at baseline—associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: A real-life observational study
Belimumab reduces disease activity, steroid use, and flares in lupus patients.
research The use of topical ruxolitinib 1.5% cream in frontal fibrosing alopecia: A case report
Topical ruxolitinib cream may help treat frontal fibrosing alopecia.
research COMPARISON OF EFFECTIVENESS OF TOPICAL TACROLIMUS AND BETAMETHASONE WITH SOFT PARAFFIN IN THE TREATMENT OF PATCHY ALOPECIA AREATA
Betamethasone is more effective than Tacrolimus and soft paraffin for hair regrowth in patchy alopecia areata.
research Trichodysplasia Spinulosa: Rare Presentation of Polyomavirus Infection in Immunocompromised Patients
Antiviral medication valganciclovir may improve skin and hair in Trichodysplasia Spinulosa patients.